The 96-week outcomes and pharmacokinetics of long-acting cabotegravir plus rilpivirine in South Africans
{{output}}
Background: Evaluating long-term efficacy, safety and pharmacokinetics of long-acting cabotegravir + rilpivirine (CAB+RPV LA) in sub-Saharan African populations is important because of the region's unique demographics and antire... ...
